Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States
- 1 June 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (6) , 2716-2719
- https://doi.org/10.1128/aac.01797-09
Abstract
The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 microg/ml and the MIC(90)s being <0.008 to 0.25 microg/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.Keywords
This publication has 20 references indexed in Scilit:
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Occurrence, Distribution, and Origins of Streptococcus pneumoniae Serotype 6C, a Recently Recognized SerotypeJournal of Clinical Microbiology, 2008
- In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Changes in Serotypes and Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Strains in Cleveland: a Quarter Century of ExperienceJournal of Clinical Microbiology, 2008
- Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in ChildrenJAMA, 2007
- Genetic Basis for the New Pneumococcal Serotype, 6CInfection and Immunity, 2007
- In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis ModelAntimicrobial Agents and Chemotherapy, 2007
- Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine CoverageJAMA, 2007
- Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic TargetAntimicrobial Agents and Chemotherapy, 2006